Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy

Author:

Cho Hourin1,Abe Seiichiro1ORCID,Nonaka Satoru1,Suzuki Haruhisa1,Yoshinaga Shigetaka1,Okuma Kae2,Yamamoto Shun3,Daiko Hiroyuki4ORCID,Kato Ken56,Sekine Shigeki7,Boku Narikazu8,Saito Yutaka1

Affiliation:

1. Endoscopy Division, National Cancer Center Hospital , Tokyo , Japan

2. Department of Radiation Oncology, National Cancer Center Hospital , Tokyo , Japan

3. Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital , Tokyo , Japan

4. Department of Esophageal Surgery, National Cancer Center Hospital , Tokyo , Japan

5. Department of Head and Neck , Esophageal Medical Oncology, , Tokyo , Japan

6. National Cancer Center Hospital , Esophageal Medical Oncology, , Tokyo , Japan

7. Division of Diagnostic Pathology, National Cancer Center Hospital , Tokyo , Japan

8. Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital , Tokyo , Japan

Abstract

Summary Endoscopic resection (ER) of esophageal squamous cell carcinoma (ESCC) is evaluated pathologically, and additional treatment is recommended for cases resulting in non-curative resection, defined as pMM with lymphovascular invasion (LVI), pSM, or positive vertical margin. This study aimed to assess long-term outcomes and risk factors for recurrence in patients with ESCC treated with non-curative ER followed by additional chemoradiotherapy (CRT). We retrospectively reviewed the clinical courses of patients who underwent non-curative ER followed by additional CRT for ESCCs between August 2007 and December 2017. Recurrence rates and risk factors for recurrence were analyzed. Among 97 patients with non-curative ER, 73 underwent additional CRT. With a median follow-up period of 71 months, recurrences were observed in 10 (14%) of 73 patients, with a median interval of 24.5 (1–59 months). The 3- and 5-year recurrence-free survival were 89 and 85%, respectively, and the 3- and 5-year overall survival rates were 96 and 91%, respectively. Multivariate analysis showed that lymphatic invasion was an independent risk factor for recurrence in patients with non-curative ESCC receiving additional CRT. Among the 10 patients with recurrence, 4, 3, 2, and 1 underwent surgery, chemotherapy, supportive care, and CRT, respectively. Notably, all four patients who underwent surgery survived, regardless of regional and/or distant lymph node metastasis. Lymphatic invasion is an independent risk factor for the recurrence of non-curative ESCCs. Careful follow-up is required for at least 5 years after ER with additional CRT.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3